27 results about "Mucoadhesion" patented technology

A functionalized tamarind seed polysaccharide, and a process for its preparation. In particular, said functionalized tamarind seed polysaccharide is a TSP having a selected functionalization degree and molecular weight, showing improved mucoadhesive properties, as well as stability and compatibility with pharmaceutical ingredients. Therefore, the invention also relates to a pharmaceutical composition, as well as a biomaterial, comprising said f-TSP.

A complex consisting of lipoic acid or a salt thereof, a chelating agent such as a salt of ethylene diamine tetraacetic acid (EDTA) or analogous compounds and an ester of ascorbic acid with long-chain fatty acids, in particular ascorbyl palmitate inhibits the pigmentation of teeth induced by chlorhexidine and salts thereof. In addition to the depigmenting complex, the formulations of the invention, in the form of gels, mouthwashes, toothpastes or periodontal sprays, may contain other ingredients such as hyaluronic acid or hyaluronates, glycerophosphocholine, sweeteners, flavourings, buffering agents, viscosifying agents, mucoadhesive and filming agents, solvents, co-solvents, surfactants.

The application discloses a liposome drug carrier with mucosal adhesion, a preparation method and application thereof, and specifically, the drug carrier is DSPE-PEG-PBA, which can be used for loading cyclosporine A and crocin I, and the carrier of the application is used for loading cyclosporine A and crocin I. The liposome loaded with the two drugs has good stability and adhesion, can inhibit the side effect of cyclosporine A on the increase of ROS level, and has a wide application prospect in the treatment of inflammation and epithelial tissue damage.

A film and a method for use thereof such as for the administration of a biologically active agent or for therapy are provided. Specifically, a film, composed of a biodegradable material having a mucoadhesive surface comprising a plurality of mushroom-type structures is provided.

Mucoadhesive microgel compositions, which include an active agent (such as HB-EGF), are provided. Aspects of the invention include a microgel comprising a crosslinked poly(ethylene glycol) methyl ether methacrylate polymer comprising a mucoadhesive functionality. Also provided are methods of making and using the mucoadhesive microgel compositions, e.g., in therapeutic applications. In one embodiment, HB-EGF loaded mucoadhesive microgel compositions are provided, e.g., for prevention or treatment of mucositis conditions, such as therapy induced oral mucositis conditions.

The present application relates to compositions and methods for: (a) preventing or treating viral infections; and / or (b) preventing the transmission and / or spread of infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a virus, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating viral infections, preventing the transmission of a viral infection from an infected individual to a non-infected individual, and for preventing the spread of a viral infection within a population of individuals.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

Described herein are mucoadhesive pharmaceutical compositions of corticosteroids, as well as methods of making such pharmaceutical compositions, and therapeutic methods using them. The compositions typically comprise a corticosteroid in a mucoadhesive system, wherein the mucoadhesive system comprises a rheology-modifying agent and a vehicle for the corticosteroid. The compositions are particularly useful for treating inflammatory conditions of the esophagus, such as eosinophilic esophagitis, or inflammatory bowel disease.

The present invention relates to an applicator (100) for arranging a mucoadhesive surface (202), in particular a mucoadhesive film (204) loaded with an active agent (e.g., a drug), on the nasal or oral mucosa, in particular buccal mucosa of a patient, the invention also relates to a disposable component for use with an applicator for arranging a mucoadhesive surface on a nasal mucosa or oral mucosa of a patient, and to a kit, the kit includes a disposable component having a mucoadhesive surface and an applicator for disposing the mucoadhesive surface on a nasal or oral mucosa of a patient.

A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having different water solubility embedded therewithin; and use thereof such as for the treatment of a disease is provided.

A pharmaceutical mucoadhesive gel composition for delivering therapeutic agents (such as progesterone) by buccal, nasal, vaginal and rectal administration, thereby avoiding the hepatic first-pass metabolism. The gel composition comprises a vehicle with a gel-forming agent and a bioadhesive agent; and a therapeutic agent dispersed or suspended in the vehicle.

Disclosed are topical compositions comprising hyaluronic acid or salts thereof and iota-carrageenan, preferably in a mucoadhesive matrix containing ascorbyl palmitate and choline alfoscerate. The compositions according to the invention are useful for topical treatment of Herpesvirus infections.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa.

The invention relates to formulations for water-insoluble active pharmaceutical ingredients. More particularly, the invention relates to a mucoadhesive patch consisting of a first layer consisting of a mucoadhesive film and a second layer consisting of a self-emulsifying drug delivery system (SEDDS) lipid microstructure for delivery of a poor water-soluble active pharmaceutical ingredient or a water insoluble active pharmaceutical ingredient.

The present invention relates to a mucoadhesive layer for buccal administration of an active pharmaceutical ingredient (API), and to a method of preparing such mucoadhesive layer. Moreover, the present invention also relates to a mucoadhesive film comprising a mucoadhesive layer for buccal administration of an active pharmaceutical ingredient, and to a method of preparing such mucoadhesive film.

The present invention relates to the formulation of innovative pharmaceutical compositions for buccal use for use in the treatment and prevention of mucocutaneous diseases of the oral cavity. Said pharmaceutical compositions are able to resist salivary re-washing and have a high substantivity on the oral mucous membranes, obtaining a massive topical effect with the minimum possible systemic assimilation.

The present invention relates to a system for oral delivery of an active ingredient, the system comprising a mucosal adhesion layer and a backing layer containing the active ingredient.

The invention relates to formulations for water-insoluble active pharmaceutical ingredients. More particularly, the invention relates to a mucoadhesive patch consisting of a first layer consisting of a mucoadhesive film and a second layer consisting of a self-emulsifying drug delivery system (SEDDS) lipid microstructure for delivery of a poor water-soluble active pharmaceutical ingredient or a water insoluble active pharmaceutical ingredient.

A system is disclosed for delivery of a therapeutic agent to a site in mucosal tissue or to the skin of a patient. The system includes a porous mucoadhesive, freeze-dried matrix formed by a composition including chitosan in an aqueous salt solution of a chloride salt of a monovalent cation. The system further includes a plurality of chitosan microparticles having an average diameter between 500 nm and 2000 nm and comprising a therapeutic agent.

This invention relates to a recombinant *Lactococcus lactis* microcapsule, its preparation method, and its applications, belonging to the field of genetic engineering. To address the technical problems of low safety, high side effects, unstable efficacy, and insufficient targeting in existing methods for treating or alleviating inflammatory bowel disease (IBD), this invention provides a recombinant *Lactococcus lactis* microcapsule. By integrating a fusion gene encoding catalase and superoxide dismutase, a recombinant *Lactococcus lactis* with antioxidant function is constructed. The recombinant *Lactococcus lactis* is then coated with a mucosa-adhesive chitosan and sodium alginate composite nanomaterial to obtain a microcapsule with antioxidant enzyme expression capabilities and a nano-protective coating. The recombinant *Lactococcus lactis* microcapsule provided by this invention can enhance the activity and bioavailability of orally delivered substances under the harsh acidic environment and complex physiological barriers of the gastrointestinal tract, providing a new strategy and experimental evidence for the clinical prevention and treatment of IBD.

The present application provides chimeric proteins comprising an antibody moiety that specifically binds to a component of an influenza virus or a variant thereof, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating an infection caused by an influenza virus or a variant thereof in an individual.

The present patent application concerns a formulation comprising: a mucoadhesive, washout-resistant and film-forming association, consisting of: a first element consisting of at least one water-soluble cellulose derivative, a second element selected from the group consisting of: at least one plant food polysaccharide, at least one glycosaminoglycan, and combinations of the foregoing; suitable excipients and diluents, wherein the weight ratio between the amount of the first element and the amount of the second element is comprised between 1:0.05 and 1:0.8.

The present application relates to compositions and methods for: (a) preventing or treating viral infections; and / or (b) preventing the transmission and / or spread of infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a virus, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating viral infections, preventing the transmission of a viral infection from an infected individual to a non-infected individual, and for preventing the spread of a viral infection within a population of individuals.

The invention relates to the technical field of pharmaceutical compositions, in particular to an albendazole suspension preparation and a preparation method thereof.The albendazole suspension preparation is obtained by mixing an albendazole inclusion compound, propylene glycol, a thickener, an emulsifier, a preservative, a stabilizer, a suspending aid, an antioxidant, deionized water and an acidity regulator, the albendazole clathrate compound is prepared from albendazole, chitosan and hydroxypropyl-beta-cyclodextrin, the hydroxypropyl-beta-cyclodextrin has a hydrophilic outer surface and a lipophilic central cavity, and the hydrophobic interaction of the hydroxypropyl-beta-cyclodextrin can accommodate a lipophilic drug albendazole, so that the solubility and the stability of the albendazole can be effectively improved, and the albendazole clathrate compound can be used for preparing a medicine for treating the albendazole. The albendazole clathrate compound has the advantages that the albendazole clathrate compound is prepared from hydroxypropyl-beta-cyclodextrin and chitosan, the chitosan has mucous membrane adhesion, the stagnation time of the albendazole clathrate compound on gastrointestinal mucosa is prolonged by grafting the chitosan to the surface of the hydroxypropyl-beta-cyclodextrin, the absorbability and bioavailability of gastrointestinal tracts are further improved, the albendazole clathrate compound and the hydroxypropyl-beta-cyclodextrin have a synergistic effect, the drug effect of the albendazole is improved, and the albendazole clathrate compound has a wide application prospect.